Stefanie Huttelmaier

Stefanie Huttelmaier

Auto-generated profile, based on publicly available information

Stefanie Huttelmaier

Department of Civil and Environmental Engineering, Northwestern University, Evanston, Illinois, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
TIThomas Ipoutcha
Thomas Ipoutcha
RRRatanachat Racharaks
Ratanachat Racharaks
SHStefanie Huttelmaier
Stefanie Huttelmaier
CWCole J. Wilson
Cole J. Wilson
EOEgon Anderson Ozer
Egon Anderson Ozer
EHErica M. Hartmann
Erica M. Hartmann
The rise in the frequency of antibiotic resistance has made bacterial infections, specifically Pseudomonas aeruginosa , a cause for greater concern. Phage therapy is a promising solution that uses naturally isolated phages to treat bacterial infections. Ecological limitations, which stipulate a discrete host range and the inevitable evolution of resistance, may be overcome through a better understanding of phage biology and the utilization of engineered phages. In this study, we developed a synthetic biology approach to construct tailed phages that naturally target clinically relevant strains of Pseudomonas aeruginosa . As proof of concept, we successfully cloned and assembled the JG024 and DMS3 phage genomes in yeast using transformation-associated recombination cloning and rebooted these two phage genomes in two different strains of P. aeruginosa . We identified factors that affected phage reboot efficiency like the phage species or the presence of antiviral defense systems in the bacterial strain. We have successfully extended this method to two other phage species and observed that the method enables the reboot of phages that are naturally unable to infect the strain used for reboot. This research represents a critical step toward the construction of clinically relevant, engineered P. aeruginosa phages. IMPORTANCE: Pseudomonas aeruginosa is a bacterium responsible for severe infections and a common major complication in cystic fibrosis. The use of antibiotics to treat bacterial infections has become increasingly difficult as antibiotic resistance has become more prevalent. Phage therapy is an alternative solution that is already being used in some European countries, but its use is limited by the narrow host range due to the phage receptor specificity, the presence of antiviral defense systems in the bacterial strain, and the possible emergence of phage resistance. In this study, we demonstrate the use of a synthetic biology approach to construct and reboot clinically relevant P. aeruginosa tailed phages. This method enables a significant expansion of possibilities through the construction of engineered phages for therapy applications.

4 December 2025 in Environmental Science: Nano
Verified
Journal Article
Open access
PDF file
SWShushan Wu
Shushan Wu
SHStefanie Huttelmaier
Stefanie Huttelmaier
JSJack Sumner
Jack Sumner
EHErica M. Hartmann
Erica M. Hartmann
KGKimberly Gray
Kimberly Gray
Under light n-TiO 2 or n-Ag increased infection by phage f1 while the ENM mixtures suppressed the effect, despite enhanced membrane permeability, F-pili gene expression, and pili density, providing mechanistic insights into ENMs' ecological impacts.

24 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TIThomas Ipoutcha
Thomas Ipoutcha
RRRatanachat Racharaks
Ratanachat Racharaks
SHStefanie Huttelmaier
Stefanie Huttelmaier
CWCole J Wilson
Cole J Wilson
EOEgon Anderson Ozer
Egon Anderson Ozer
EHErica M. Hartmann
Erica M. Hartmann
The rise in frequency of antibiotic resistance has made bacterial infections, specifically Pseudomonas aeruginosa , a cause for greater concern. Phage therapy is a promising solution that uses naturally isolated phages to treat bacterial infections. Ecological limitations, which stipulate a discrete host range and the inevitable evolution of resistance, may be overcome through a better understanding of phage biology and the utilization of engineered phages. In this study, we developed a synthetic biology approach to construct tailed phages that naturally target clinically-relevant strains of Pseudomonas aeruginosa . As proof of concept, we successfully cloned and assembled the JG024 and DMS3 phage genomes in yeast using transformation-associated recombination (TAR) cloning and rebooted these two phage genomes in two different strains of P. aeruginosa . We identified factors that affected phage reboot efficiency like the phage species or the presence of antiviral defense systems in the bacterial strain. We have successfully extended this method to two other phage species and observed that the method enables the reboot of phages that are naturally unable to infect the strain used for reboot. This research represents a critical step towards the construction of clinically-relevant, engineered P. aeruginosa phages. Importance: Pseudomonas aeruginosa is a bacterium responsible for severe infections and a common major complication in cystic fibrosis. The use of antibiotics to treat bacterial infections has become increasingly difficult as antibiotic resistance has become more prevalent. Phage therapy is an alternative solution that is already being used in some European countries, but its use is limited by narrow host range due to the phage receptor specificity, the presence of antiviral defense systems in the bacterial strain, and the possible emergence of phage resistance. In this study, we demonstrate the use of a synthetic biology approach to construct and reboot clinically-relevant P. aeruginosa tailed phages. This method enables a significant expansion of possibilities through the construction of engineered phages for therapy applications.